Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.

@article{Puskas2011DevelopmentOA,
  title={Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.},
  author={John D. Puskas and Denise Skrombolas and Abigail L Sedlacek and Edith M. Lord and Mark R. Sullivan and John G. Frelinger},
  journal={Immunology},
  year={2011},
  volume={133 2},
  pages={
          206-20
        }
}
The ability to alter the cytokine microenvironment has the potential to shape immune responses in many physiological settings, including the immunotherapy of tumours. We set out to develop a general approach in which cytokines could be functionally attenuated until activated. We report the development and initial characterization of fusion proteins in which human or mouse interleukin-2 (IL-2), a potent growth factor for immune cells, is joined to a specific IL-2 inhibitory binding component… CONTINUE READING
BETA
1
Twitter Mention

Similar Papers